Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2010

Open Access 01-12-2010 | Short communication

Depletion of the oncoprotein Bcl-3 induces centrosome amplification and aneuploidy in cancer cells

Authors: Ruben Zamora, Magali Espinosa, Gisela Ceballos-Cancino, Blanca Segura, Vilma Maldonado, Jorge Melendez-Zajgla

Published in: Molecular Cancer | Issue 1/2010

Login to get access

Abstract

Bcl-3 is an atypical member of the inhibitor of NF-kappa B family of proteins since it can function as a coactivator of transcription. Although this oncogene was described in leukemia, it is overexpressed in a number of solid tumors as well. The oncogenic potential of Bcl-3 has been associated with its capacity to increase proliferation by means of activating the cyclin D1 promoter and to its antiapoptotic role mediated by the inhibiton of p53 activity. In the course of dissecting these properties, we found that depleting Bcl-3 protein using shRNAs induce a decrease of proliferation and clonogenic survival associated with the induction of multinucleation and increased ploidy. These effects were associated with a DNA damage response, a delay in G2/M checkpoint and the induction of centrosome amplification
Appendix
Available only for authorised users
Literature
1.
Crossen PE: Cytogenetic and molecular changes in chronic B-cell leukemia. Cancer Genet Cytogenet. 1989, 43 (2): 143-150. 10.1016/0165-4608(89)90027-7CrossRefPubMed
2.
Ohno H, Takimoto G, McKeithan TW: The candidate proto-oncogene bcl-3 is related to genes implicated in cell lineage determination and cell cycle control. Cell. 1990, 60 (6): 991-997. 10.1016/0092-8674(90)90347-HCrossRefPubMed
3.
Bours V, Franzoso G, Azarenko V, Park S, Kanno T, Brown K, Siebenlist U: The oncoprotein Bcl-3 directly transactivates through kappa B motifs via association with DNA-binding p50B homodimers. Cell. 1993, 72 (5): 729-739. 10.1016/0092-8674(93)90401-BCrossRefPubMed
4.
Dechend R, Hirano F, Lehmann K, Heissmeyer V, Ansieau S, Wulczyn FG, Scheidereit C, Leutz A: The Bcl-3 oncoprotein acts as a bridging factor between NF-kappaB/Rel and nuclear co-regulators. Oncogene. 1999, 18 (22): 3316-3323. 10.1038/sj.onc.1202717CrossRefPubMed
5.
Fujita T, Nolan GP, Liou HC, Scott ML, Baltimore D: The candidate proto-oncogene bcl-3 encodes a transcriptional coactivator that activates through NF-kappa B p50 homodimers. Genes Dev. 1993, 7 (7B): 1354-1363. 10.1101/gad.7.7b.1354CrossRefPubMed
6.
Na SY, Choi JE, Kim HJ, Jhun BH, Lee YC, Lee JW: Bcl3, an IkappaB protein, stimulates activating protein-1 transactivation and cellular proliferation. J Biol Chem. 1999, 274 (40): 28491-28496. 10.1074/jbc.274.40.28491CrossRefPubMed
7.
Cogswell PC, Guttridge DC, Funkhouser WK, Baldwin AS: Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3. Oncogene. 2000, 19 (9): 1123-1131. 10.1038/sj.onc.1203412CrossRefPubMed
8.
Thornburg NJ, Pathmanathan R, Raab-Traub N: Activation of nuclear factor-kappaB p50 homodimer/Bcl-3 complexes in nasopharyngeal carcinoma. Cancer Res. 2003, 63 (23): 8293-8301.PubMed
9.
Pallares J, Martinez-Guitarte JL, Dolcet X, Llobet D, Rue M, Palacios J, Prat J, Matias-Guiu X: Abnormalities in the NF-kappaB family and related proteins in endometrial carcinoma. J Pathol. 2004, 204 (5): 569-577. 10.1002/path.1666CrossRefPubMed
10.
Westerheide SD, Mayo MW, Anest V, Hanson JL, Baldwin AS: The putative oncoprotein Bcl-3 induces cyclin D1 to stimulate G(1) transition. Mol Cell Biol. 2001, 21 (24): 8428-8436. 10.1128/MCB.21.24.8428-8436.2001PubMedCentralCrossRefPubMed
11.
Massoumi R, Chmielarska K, Hennecke K, Pfeifer A, Fassler R: Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling. Cell. 2006, 125 (4): 665-677. 10.1016/j.cell.2006.03.041CrossRefPubMed
12.
Kashatus D, Cogswell P, Baldwin AS: Expression of the Bcl-3 proto-oncogene suppresses p53 activation. Genes Dev. 2006, 20 (2): 225-235. 10.1101/gad.1352206PubMedCentralCrossRefPubMed
13.
Dodson H, Bourke E, Jeffers LJ, Vagnarelli P, Sonoda E, Takeda S, Earnshaw WC, Merdes A, Morrison C: Centrosome amplification induced by DNA damage occurs during a prolonged G2 phase and involves ATM. EMBO J. 2004, 23 (19): 3864-3873. 10.1038/sj.emboj.7600393PubMedCentralCrossRefPubMed
14.
Reinhardt HC, Yaffe MB: Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2. Curr Opin Cell Biol. 2009, 21 (2): 245-255. 10.1016/j.ceb.2009.01.018PubMedCentralCrossRefPubMed
15.
Bartek J, Lukas J: Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell. 2003, 3 (5): 421-429. 10.1016/S1535-6108(03)00110-7CrossRefPubMed
16.
Brinkley BR: Managing the centrosome numbers game: from chaos to stability in cancer cell division. Trends Cell Biol. 2001, 11 (1): 18-21. 10.1016/S0962-8924(00)01872-9CrossRefPubMed
17.
Meraldi P, Honda R, Nigg EA: Aurora-A overexpression reveals tetraploidization as a major route to centrosome amplification in p53-/- cells. EMBO J. 2002, 21 (4): 483-492. 10.1093/emboj/21.4.483PubMedCentralCrossRefPubMed
18.
Bourke E, Dodson H, Merdes A, Cuffe L, Zachos G, Walker M, Gillespie D, Morrison CG: DNA damage induces Chk1-dependent centrosome amplification. EMBO Rep. 2007, 8 (6): 603-609. 10.1038/sj.embor.7400962PubMedCentralCrossRefPubMed
19.
Boulton SJ, Gartner A, Reboul J, Vaglio P, Dyson N, Hill DE, Vidal M: Combined functional genomic maps of the C. elegans DNA damage response. Science. 2002, 295 (5552): 127-131. 10.1126/science.1065986CrossRefPubMed
20.
Watanabe N, Wachi S, Fujita T: Identification and characterization of BCL-3-binding protein: implications for transcription and DNA repair or recombination. J Biol Chem. 2003, 278 (28): 26102-26110.CrossRefPubMed
Metadata
Title
Depletion of the oncoprotein Bcl-3 induces centrosome amplification and aneuploidy in cancer cells
Authors
Ruben Zamora
Magali Espinosa
Gisela Ceballos-Cancino
Blanca Segura
Vilma Maldonado
Jorge Melendez-Zajgla
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2010
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-9-223

Other articles of this Issue 1/2010

Molecular Cancer 1/2010 Go to the issue

Research

Identification of tumor-associated cassette exons in human cancer through EST-based computational prediction and experimental validation

Research

Cathepsin B inhibition interferes with metastatic potential of human melanoma: an in vitro and in vivo study

Research

Replication independent DNA double-strand break retention may prevent genomic instability

Research

A biology-driven approach identifies the hypoxia gene signature as a predictor of the outcome of neuroblastoma patients

Short communication

VHZ is a novel centrosomal phosphatase associated with cell growth and human primary cancers

Research

Interaction between circulating galectin-3 and cancer-associated MUC1 enhances tumour cell homotypic aggregation and prevents anoikis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits